Publication | Closed Access

The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia

Cerebral Vascular RegulationBrain DamageMedicineCell DeathNeuropharmacologyP38 MapkBrain InjuryNeuroscienceNeurologyNeuroprotectionCerebral Blood FlowNeurological DeficitPharmacologyNeurochemistryIschemic SyndromeReperfusion Injury